Developer docs
API playgroundTry for free, no card

Search company profiles

Forbius

Full company profile

uuid0002zeo

Namestring
Forbius
Legal namestring
Forbius
Websiteurl
forbius.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Forbius is a privately held, clinical-stage biopharmaceutical company founded in 2011 and headquartered in Austin, Texas. The company develops and designs biotherapeutics aimed at the treatment of fibrotic diseases and cancers, operating across two distinct therapeutic verticals that broaden its potential indication footprint. Its leadership team is oriented around research and development, comprising a Chief Scientific Officer, Chief Medical Officer, Chief Development Officer, and a Director of Preclinical Development, consistent with a company advancing candidates through preclinical and clinical stages rather than operating a commercial product franchise.

Forbius has funded its operations through a series of equity rounds and non-dilutive translational grants since 2012, drawing capital from healthcare-focused investors including HBM Partners, HBM Healthcare Investments, Lumira Ventures, and Rosseau Asset Management, alongside translational funders such as the Cancer Prevention and Research Institute of Texas and BioCanRx. The largest single disclosed capital event was an $18.8 million award from CPRIT in August 2018. The company has not disclosed any marketed product, pricing model, partnership economics, or revenue, and its public-facing website is limited to a contact form and an email signup, with no pipeline detail publicly available.

The company's revenue model is not yet defined commercially; as a pre-revenue developer, economics will ultimately depend on licensing, partnership, or royalty structures once any candidate reaches a commercial milestone. End customers, if and when products reach market, would be healthcare providers and payers rather than direct enterprise buyers, and customer concentration risk for any future revenue cannot be assessed from current evidence.

Short descriptiontext

Forbius is a clinical-stage biopharmaceutical company founded in 2011 that develops biotherapeutics for the treatment of fibrotic diseases and cancers, headquartered in Austin, Texas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotherapeutic drug development, fibrotic disease therapeutics, oncology biologics, clinical-stage biopharmaceuticals, protein engineering platform
Industry1 code
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-Stage Biopharmaceuticals
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Forbius is a clinical-stage biopharmaceutical company that designs and develops biotherapeutics for the treatment of fibrotic diseases and cancers. The company operates a focused R&D organization advancing biologic drug candidates through preclinical and early clinical development, with the intent to bring targeted protein-based medicines to patients in high-unmet-need indications.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Biotherapeutic pipeline for fibrotic diseases
CategoryBiotherapeutic drug candidates
Description

Pipeline of biotherapeutic drug candidates being designed and developed by Forbius for the treatment of fibrotic diseases; intended for eventual out-licensing, partnership, or commercialization with larger pharmaceutical companies serving patients with fibrosis.

2Biotherapeutic pipeline for cancers
CategoryBiotherapeutic drug candidates
Description

Pipeline of biotherapeutic drug candidates being designed and developed by Forbius for the treatment of cancers; intended for eventual out-licensing, partnership, or commercialization with larger pharmaceutical companies serving oncology patients.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage biotech with fibrosis programs (e.g., BBP-418 for LGMD, infigratinib for achondroplasia). BridgeBio is comparable via its fibrosis franchise, though it operates at a much larger scale.

TypeBroad incumbent
Description

Global biopharma with deep biologic oncology and fibrosis capabilities. Roche is a natural strategic acquirer for any specialized biologic platform in fibrosis or oncology.

TypeDirect peer
Description

Clinical-stage biotech with significant fibrosis and inflammation programs, including partnerships with larger pharma. Galapagos is comparable to Forbius on fibrosis indication and biologic modality.

TypeDirect peer
Description

Clinical-stage biotech developing integrin-targeted therapeutics for fibrotic diseases. Pliant is directly comparable to Forbius in therapeutic area (fibrosis), modality (biologics), and corporate stage (clinical).

5Morphic Holding
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin inhibitors for fibrosis and autoimmune disease. Morphic overlaps with Forbius on fibrosis biology, though its small-molecule approach differs in modality.

TypeBroad incumbent
Description

Commercial-stage biopharma with pulmonary fibrosis and pulmonary hypertension franchises. United Therapeutics is a relevant incumbent reference point for fibrosis drug development and commercial dynamics.

TypeDirect peer
Description

Clinical-stage biotech developing biologics that target TGF-beta activation, with a focus on fibrosis and oncology. Scholar Rock is the closest mechanistic peer to Forbius's TGF-beta biology work and shares the same fibrosis/cancer therapeutic positioning.

TypeDirect peer
Description

Late-stage biopharma developing therapeutics for fibrosis and anemia. FibroGen directly overlaps Forbius on fibrosis indication and biologic modality, and serves as a useful scale-up reference.

9Boehringer Ingelheim
TypeBroad incumbent
Description

Large pharma with a leading idiopathic pulmonary fibrosis franchise (nintedanib). Boehringer is a relevant incumbent that defines the competitive standard Forbius's fibrosis programs must beat.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Global biopharma with active fibrosis and oncology biologics portfolios. BMS is a relevant acquirer profile for specialty biologics in fibrosis/cancer, comparable in therapeutic focus if not in scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Forbius

Clinical-Stage Biopharmaceuticalsforbius.com

Forbius is a clinical-stage biopharmaceutical company founded in 2011 that develops biotherapeutics for the treatment of fibrotic diseases and cancers, headquartered in Austin, Texas.

What Forbius does

Forbius is a privately held, clinical-stage biopharmaceutical company founded in 2011 and headquartered in Austin, Texas. The company develops and designs biotherapeutics aimed at the treatment of fibrotic diseases and cancers, operating across two distinct therapeutic verticals that broaden its potential indication footprint. Its leadership team is oriented around research and development, comprising a Chief Scientific Officer, Chief Medical Officer, Chief Development Officer, and a Director of Preclinical Development, consistent with a company advancing candidates through preclinical and clinical stages rather than operating a commercial product franchise.

Forbius has funded its operations through a series of equity rounds and non-dilutive translational grants since 2012, drawing capital from healthcare-focused investors including HBM Partners, HBM Healthcare Investments, Lumira Ventures, and Rosseau Asset Management, alongside translational funders such as the Cancer Prevention and Research Institute of Texas and BioCanRx. The largest single disclosed capital event was an $18.8 million award from CPRIT in August 2018. The company has not disclosed any marketed product, pricing model, partnership economics, or revenue, and its public-facing website is limited to a contact form and an email signup, with no pipeline detail publicly available.

The company's revenue model is not yet defined commercially; as a pre-revenue developer, economics will ultimately depend on licensing, partnership, or royalty structures once any candidate reaches a commercial milestone. End customers, if and when products reach market, would be healthcare providers and payers rather than direct enterprise buyers, and customer concentration risk for any future revenue cannot be assessed from current evidence.

Forbius firmographics

Firmographics
Name
Forbius
Legal name
Forbius
Website
https://forbius.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Forbius is a clinical-stage biopharmaceutical company founded in 2011 that develops biotherapeutics for the treatment of fibrotic diseases and cancers, headquartered in Austin, Texas.
Ownership category
akta.pro rank

Forbius industry classification

Industry
Product category
Clinical-Stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Biotherapeutic drug development
  • Fibrotic disease therapeutics
  • Oncology biologics
  • Clinical-stage biopharmaceuticals
  • Protein engineering platform

Where Forbius is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Markets served

Forbius business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Distribution channels1 record

Marketing channels1 record

Forbius product offering

Product offering

Core offering

Forbius is a clinical-stage biopharmaceutical company that designs and develops biotherapeutics for the treatment of fibrotic diseases and cancers. The company operates a focused R&D organization advancing biologic drug candidates through preclinical and early clinical development, with the intent to bring targeted protein-based medicines to patients in high-unmet-need indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biotherapeutic pipeline for fibrotic diseases Pipeline of biotherapeutic drug candidates being designed and developed by Forbius for the treatment of fibrotic diseases; intended for eventual out-licensing, partnership, or commercialization with larger pharmaceutical companies serving patients with fibrosis.
  • Biotherapeutic pipeline for cancers Pipeline of biotherapeutic drug candidates being designed and developed by Forbius for the treatment of cancers; intended for eventual out-licensing, partnership, or commercialization with larger pharmaceutical companies serving oncology patients.

Companies that use Forbius

Customer profile

Ideal customer profiles1 record

Forbius technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Forbius partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

Forbius competitors and assessment

Company assessment

Emerging players

  • BridgeBio Pharma: Clinical-stage biotech with fibrosis programs (e.g., BBP-418 for LGMD, infigratinib for achondroplasia). BridgeBio is comparable via its fibrosis franchise, though it operates at a much larger scale.

Broad incumbents

  • Roche: Global biopharma with deep biologic oncology and fibrosis capabilities. Roche is a natural strategic acquirer for any specialized biologic platform in fibrosis or oncology.
  • United Therapeutics: Commercial-stage biopharma with pulmonary fibrosis and pulmonary hypertension franchises. United Therapeutics is a relevant incumbent reference point for fibrosis drug development and commercial dynamics.
  • Boehringer Ingelheim: Large pharma with a leading idiopathic pulmonary fibrosis franchise (nintedanib). Boehringer is a relevant incumbent that defines the competitive standard Forbius's fibrosis programs must beat.
  • Bristol-Myers Squibb: Global biopharma with active fibrosis and oncology biologics portfolios. BMS is a relevant acquirer profile for specialty biologics in fibrosis/cancer, comparable in therapeutic focus if not in scale.

Direct peers

  • Galapagos NV: Clinical-stage biotech with significant fibrosis and inflammation programs, including partnerships with larger pharma. Galapagos is comparable to Forbius on fibrosis indication and biologic modality.
  • Pliant Therapeutics: Clinical-stage biotech developing integrin-targeted therapeutics for fibrotic diseases. Pliant is directly comparable to Forbius in therapeutic area (fibrosis), modality (biologics), and corporate stage (clinical).
  • Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for fibrosis and autoimmune disease. Morphic overlaps with Forbius on fibrosis biology, though its small-molecule approach differs in modality.
  • Scholar Rock: Clinical-stage biotech developing biologics that target TGF-beta activation, with a focus on fibrosis and oncology. Scholar Rock is the closest mechanistic peer to Forbius's TGF-beta biology work and shares the same fibrosis/cancer therapeutic positioning.
  • FibroGen: Late-stage biopharma developing therapeutics for fibrosis and anemia. FibroGen directly overlaps Forbius on fibrosis indication and biologic modality, and serves as a useful scale-up reference.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Forbius social profiles

Digital presence

Forbius financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Forbius leadership team

Management profile

Number of profiles

Profiles4 records

Forbius funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Forbius M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Forbius

What does Forbius do?

Forbius is a clinical-stage biopharmaceutical company that designs and develops biotherapeutics for the treatment of fibrotic diseases and cancers. The company operates a focused R&D organization advancing biologic drug candidates through preclinical and early clinical development, with the intent to bring targeted protein-based medicines to patients in high-unmet-need indications.

When was Forbius founded?

Forbius was founded in 2011. It employs 1 to 10 people.

Where is Forbius based?

Forbius is headquartered in Austin, United States, in the North America region.

Who are Forbius's main competitors?

BridgeBio Pharma is listed as an emerging player. Broad incumbents are Roche, United Therapeutics, Boehringer Ingelheim and Bristol-Myers Squibb. Direct peers are Galapagos NV, Pliant Therapeutics, Morphic Holding, Scholar Rock and FibroGen.

Does Forbius have an API?

No public API is recorded for Forbius.

What industry is Forbius in?

Forbius's product category is Clinical-Stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals